New Delhi: Torrent Pharmaceuticals today announced the launch of its Semaglutide brands – Sembolic and Semalix – in India, in both oral and injectable formulations. The launch expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity.
Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharma, said: “Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices. We are proud to be the first Indian company to offer this treatment across oral and injectable formulations, giving healthcare professionals a holistic choice for treating patients”
About GLP-1 Drug Category
GLP-1 (glucagon-like peptide-1) receptor agonists are well-established prescription medications for the management of type 2 diabetes and obesity. They work by enhancing insulin secretion, reducing glucagon levels and help regulate appetite. They have been shown to be effective at decreasing haemoglobin A1c (HbA1c), promoting weight loss and reducing the risk of cardiovascular events by mimicking the hormone GLP-1
